SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Tesla Raises Cybertruck Prices by $5,000 in US 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Nvidia Options Price in $280 Billion Earnings Swing 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Add as a preferred source on Google
CHARLESTON, S.C., May 01, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) will announce its first quarter 2018 financial and operating results after market close on Monday, May 7, 2018. The Company will host a conference call to discuss these results on Tuesday, May 8, 2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13679691
- Toll: 201-689-8029, Confirmation #13679691
A replay will also be available on the Company’s website for a period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com.
Contact:
Aeterna Zentaris Inc.
James Clavijo
Chief Financial Officer
[email protected]
843-900-3201
